BACKGROUND
Myelofibrosis (MF) is a myeloid bone marrow malignancy with a progressive clinical course marked by disease-related symptoms, splenomegaly, cytopenias, thrombosis/hemorrhage, and a risk for blast phase transformation. Treatment recommendations are based on the burden of symptoms, prognosis of the disease, an...
B. Stein, Maya Abdallah, Gregory A. Abel et al.· Blood Advances· 0 citations
Despite treatment advances, relapsed/refractory
FLT3
-ITD-mutated acute myeloid leukemia (
FLT3
-ITD
mut
AML) remains an unmet medical need. We previously identified a CD34/CD123/CD25/CD99+ leukemic progenitor cell (LPC) population that persists after induction treatment and drives disease recurrence in
FLT3...
S. Travaglini, T. Ottone, S. Antonelli et al.· Cell Death Discovery· 0 citations
Introduction
Myelofibrosis (MF) is a BRC::ABL1-negative myeloproliferative neoplasm characterised by a heterogeneous clinical phenotype encompassing abnormalities in blood counts, bone marrow fibrosis, splenomegaly, constitutional symptoms and vascular complications. MF may progress to accelerated phase (AP) and blast...
Barbara Mora, M. Franchi, L. Margotto et al.· Epidemiology Biostatistics a...· 0 citations
Relapse and non-relapse mortality after transplantation for myelofibrosis are governed by distinct dimensions, and estimating both outcomes independently with genetic and clinical information, in addition to overall survival, establishes an individualized basis for transplant decision-making.
N. Gagelmann, R. Salit, T. Schroeder et al.· Transplantation and Cellular...· 2 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.